NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-HL-16-459 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-16-018 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to initiate and implement a network of participating clinical centers to perform pilot and feasibility studies of therapies to slow or reverse the progression of chronic kidney disease (CKD) in children. This FOA invites applications for the Participating Clinical Centers (PCCs) and runs in parallel with a separate FOA that invites applications for the Data Coordinating Center (DCC) (RFA-DK-16-035). These pilot studies will seek to optimize critical elements of a full-scale randomized control trial design - the most promising study question, agent(s), target population, dosing, data collection, and appropriate outcomes. Applicants must propose two trials to be conducted sequentially over the funding period. One trial will be to lower serum uric acid levels, while the other can be an appropriately justified study question of the applicant's choosing. When applicable, clinical site investigators may enlist industry collaboration to achieve the goals of the network. The ultimate goal of this FOA is to obtain the necessary information to design and implement one or more full-scale randomized controlled clinical trials of therapies to reduce morbidity in children with CKD.
Funding Opportunity RFA-DK-16-035 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to initiate and implement a network of participating clinical centers and a data coordinating center to perform pilot and feasibility studies of therapies to slow or reverse the progression of chronic kidney disease (CKD) in children. This FOA invites applications for the Data Coordinating Center (DCC) and runs in parallel with a separate FOA that invites applications for the Participating Clinical Centers (PCCs) (RFA-DK-16-018). These pilot studies will seek to optimize critical elements of a full-scale randomized control trial design - the most promising study question, agent(s), target population, dosing, data collection, and appropriate outcomes. Applicants must propose two trial designs to be conducted sequentially over the funding period. One trial will be to lower serum uric acid levels, while the other can be an appropriately justified study question of the applicant's choosing. The ultimate goal of this FOA is to obtain the necessary information to design and implement one or more full-scale randomized controlled clinical trial of therapies to reduce morbidity in children with CKD.
Funding Opportunity PAR-17-035 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to incentivize small businesses to generate new technologies and products for delivering nucleic acids into cells and tissues for the purpose of treatment or prevention of human disease.
Funding Opportunity PAR-17-036 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to incentivize small businesses to generate new technologies and products for delivering nucleic acids into cells and tissues for the purpose of treatment or prevention of human disease.
Funding Opportunity PAR-17-034 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies. The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies.
Funding Opportunity PAR-17-039 from the NIH Guide for Grants and Contracts. This FOA invites exploratory comparative biology research projects assessing how different animal species respond to challenges and damage to cellular physiology pathways that might influence the onset of Alzheimer's and other neurodegenerative diseases as well as resilience to them, such as adaptation to stress, macromolecular damage, proteostasis and stem cell function and regeneration.
Notice NOT-NS-17-005 from the NIH Guide for Grants and Contracts
Notice NOT-NS-17-006 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-17-056 from the NIH Guide for Grants and Contracts. This FOA invites applications on descriptive, basic and translational studies of APOE2 to delineate the functional effects of ApoE2 on healthy aging of the brain and other tissues. The primary focus is on the APOE2Aging-AD" relationship and the mechanistic effects of the protective variant on aging and potential interaction/cross talk between tissues in the aging process and AD. These studies are expected to generate new mechanistic insights that involve brain and/or other organs and assist in the identification of potential prognostic and diagnostic markers and therapeutic targets for AD and other age-related cognitive disorders. Eventually, the findings from these studies could lead to translational research opportunities not only to prevent or delay the onset of AD, but also to protect against multiple age-related conditions.
Funding Opportunity RFA-AG-17-051 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the role of exosome biogenesis and secretion in modulating and propagation of early pathogenesis in sporadic and late-onset Alzheimers disease (AD). Specifically, this FOA encourages collaborative approaches designed to identify and characterize the regulation of molecular machines that are responsible for exosome biogenesis and the secretion of exosomal cargo molecules in AD.
Funding Opportunity RFA-HL-17-020 from the NIH Guide for Grants and Contracts. This FOA invites applications for clinical research to elucidate circadian-dependent mechanisms contributing to the pathophysiology of human obesity, diabetes-related metabolism, obesity-coupled risks for heart, lung, and blood disease, and the identification of novel therapies to improve circadian rhythm for primary or secondary prevention of obesity-associated disease risks. Multi-disciplinary, multiple-investigator teams proposing mechanistic clinical studies to elucidate the relationship of circadian rhythm to causal pathways of disease are encouraged. Studies of epidemiological risk and clinical trials to assess therapeutic efficacy, effectiveness, or implementation are outside the scope of this program.
Funding Opportunity PAR-17-031 from the NIH Guide for Grants and Contracts. This FOA encourages innovative experimental approaches to explore the molecular and cellular bases for age-related change in metabolism that impact the development of Alzheimer's disease (AD).
Notice NOT-HS-17-002 from the NIH Guide for Grants and Contracts
Notice NOT-DK-17-001 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-033 from the NIH Guide for Grants and Contracts. This FOA invites applications that apply a cross-disciplinary, team science approach to gain comprehensive, mechanistic understanding of the impact of sex differences on the trajectories of brain aging and phenotypes of AD risk and on the responsiveness to pharmacologic and non-pharmacologic interventions.
Funding Opportunity PAR-17-032 from the NIH Guide for Grants and Contracts. This funding opportunity invites applications that integrate the use of computational approaches to identify individual drugs currently used for other conditions with potential to be efficacious in AD or AD-related dementias (as single drugs or as drug combinations) with proof-of-concept efficacy studies in cell-based models, animal models and/or humans.
Notice NOT-AG-16-080 from the NIH Guide for Grants and Contracts
Notice NOT-AG-16-079 from the NIH Guide for Grants and Contracts
Notice NOT-AG-16-078 from the NIH Guide for Grants and Contracts